Table 4.
Long-Term Clinical Outcomes in Groups 1–4
| Group 1 (n=125) |
Group 2 (n=102) |
Group 3 (n=395) |
Group 4 (n=384) |
P value | |
|---|---|---|---|---|---|
| Follow up (days) | 1,064±842 | 1,318±806 | 1,128±860 | 1,328±803 | 0.0007 |
| MACEs (%) | 38 | 26 | 31 | 27 | 0.074 |
| Death (%) | 5.6 | 9.8 | 8.4 | 7.6 | 0.648 |
| MI (%) | 7.2 | 2.9 | 7.1 | 3.4 | 0.064 |
| TLR PCI (%) | 28 | 13 | 19 | 17 | 0.024 |
| TLR CABG (%) | 2.4 | 2 | 1.8 | 0.8 | 0.471 |
| TVR PCI (%) | 11 | 3.9 | 5.1 | 9.9 | 0.011 |
| TVR CABG (%) | 1.6 | 0 | 0.8 | 0.5 | 0.438 |
| Non-TVR PCI (%) | 28 | 28 | 31 | 26 | 0.470 |
| Non-TVR CABG (%) | 3.2 | 1.0 | 1.8 | 0.8 | 0.276 |
| CVA (%) | 3.2 | 5.9 | 3.8 | 5.5 | 0.640 |
| All coronary event (%) | 66 | 56 | 58 | 51 | 0.032 |
MACEs, major adverse cardiac events; TLR, target lesion revascularization; TVR, target vessel revascularization. Other abbreviations as in Table 1.